ACCME addresses conflict of interest

Share this article:
Peer-reviewed continuing medical education may become standard under a guidance issued this week that was welcomed by CME providers.
The Accreditation Council for Continuing Medical Education (ACCME) suggested peer reviews as a means of resolving potential conflicts of interest by physicians presenting CME that contained information on drugs made by companies from which they have accepted honoraria. The prompt came in a supplement to the revised Standards for Commercial Support, which advised: "'Peer review' of CME is often already in place and is a mechanism to resolve conflict of interest." Additionally, the provider must ensure that CME references the "best available evidence," the ACCME said in an Oct. 20 document entitled, "Additional Questions and Answers regarding the Updated 2004 Standards for Commercial Support."
CME providers and supporters were alarmed by a previous backgrounder issued by the ACCME, which many interpreted as indicating that faculty with potential conflicts of interest could not discuss their own clinical experience and would be limited to reciting previously published research data. Such a restriction would have driven many of the best CME speakers from the stage, said providers. 
"These two processes provide a roadmap that will allow for the development of policies that will meet the objectives of ACCME while including individuals that may have conflicts," said Marty Cearnal, chief strategy officer for Thomson Medical Education and an early proponent of peer reviews as a means of resolving potential conflicts.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...